Beta Preserve
Contact
Description
The purpose of this study is to measure change in glycemic control and insulin needs with Teplizumab compared with placebo. The intervention, either Teplizumab or placebo, will be administered by intravenous (IV) infusion, to participants recently diagnosed with stage 3 type 1 diabetes (T1D) aged 1 to 25 years.
Teplizumab, also known as Tzield, is currently approved for use in stage 2 type 1 diabetes, to delay the onset of stage 3 T1D in adults and children eight years and older. Teplizumab is the first and only disease modifying therapy in autoimmune T1D.
Eligibility and criteria
What to expect
Visits will be at the CHOP Philadelphia Campus
The study drug will be administered over two 12-day treatment courses, 6 months apart. Follow up visits will take place after each treatment course. The study will last 78 weeks.
Related specialties
Related conditions
We need families like you
Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.